Anti-β2-glycoprotein I antibodies

Abstract

The relationship between presence of anti-β2-glycoprotein I autoantibodies (aβ2-GPI) and history of thrombosis is now widely known. However, differences in the methodology of aβ2-GPI detection have made the comparison of data from different laboratories extremely difficult. We discuss the significance of aβ2-GPI of the IgG, IgM and IgA isotypes, and our approach to developing an easier and more reproducible method for the detection of this autoantibody. In addition, we present data that shows that commercially available enzyme immunoassay plates differ regarding detectability of aβ2-GPI. Since the clinical significance of this heterogeneity is presently unclear, the set-up of the detection systems and interpretation of data need great care.

Keywords

β2-glycoprotein I anti-β2-glycoprotein I enzyme immunoassay

Get full access to this article

View all access options for this article.

References

McNeil

, Simpson

, Chesterman

, Krilis

SA.

Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H).

Proc Natl Acad Sci USA 1990; 87: 4120–4124.

Galli

. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1544–1547.

Matsuura

. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177–178.

Koike

, Matsuura

What is the “true” antigen for anticardiolipin antibodies?

Lancet 1991; 337: 671–672.

Matsuura

. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885–3891.

Matsuura

. Anticardiolipin antibodies recognize β₂-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457–462.

Tsutsumi

. Antibodies to β₂-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466–1474.

Tsutsumi

, Matsuura

, Ichikawa

, Koike

Antibodies to β2-glycoprotein I in patients with systemic lupus erythematosus: reply.

Arthritis Rheum 1997; 40: 1366–1367.

Tsutsumi

. IgA class anti-β₂-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 74–78.

10.

McNally

. The use of an anti-β₂-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471–477.

11.

Pengo

, Biasiolo

, Fior

MG.

Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface.

Thromb Haemost 1995; 73: 29–34.

12.

Amengual

. Specificity of ELISA to β₂-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996; 35: 1239–1243.

13.

Guerin

, Feigherty

, Sim

, Jackson

Antibodies to β₂-glycoprotein I-a specific marker for the antiphospholipid syndrome.

Clin Exp Immunol 1997; 109: 304–309.

14.

Fanopoulos

, Teodorescu

, Varga

, Teodorescu

High frequency of IgA anti-β₂-glycoprotein I antibodies in patients with SLE: relationship with APS.

J Rheumatol 1998; 25: 675–680.

15.

Ichikawa

. Glycoprotein I reactivity of monoclonal anti-cardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453–1461.

16.

Igarashi

. Human β₂-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood 1996; 87: 3262–3270.

17.

Hashimoto . Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol 1992; 149: 1063–1068.